KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Receivables (2016 - 2025)

Emergent BioSolutions' Change in Receivables history spans 16 years, with the latest figure at -$51.9 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 167.32% year-over-year to -$51.9 million; the TTM value through Dec 2025 reached -$25.5 million, down 204.51%, while the annual FY2025 figure was -$25.5 million, 204.51% down from the prior year.
  • Change in Receivables reached -$51.9 million in Q4 2025 per EBS's latest filing, down from $71.6 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $132.4 million in Q2 2023 to a low of -$118.5 million in Q2 2025.
  • Average Change in Receivables over 5 years is -$4.1 million, with a median of -$12.2 million recorded in 2022.
  • The largest YoY upside for Change in Receivables was 3410.0% in 2023 against a maximum downside of 569.08% in 2023.
  • A 5-year view of Change in Receivables shows it stood at -$98.5 million in 2021, then soared by 63.86% to -$35.6 million in 2022, then dropped by 3.65% to -$36.9 million in 2023, then skyrocketed by 308.94% to $77.1 million in 2024, then plummeted by 167.32% to -$51.9 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Change in Receivables are -$51.9 million (Q4 2025), $71.6 million (Q3 2025), and -$118.5 million (Q2 2025).